Effective treatment of hyperphosphatemia with denosumab in patients with loss of function of <i>FGF23</i> and high bone density: case series
Denosumab effectively reduced serum phosphate and improved symptoms in patients with <i>FGF23</i>-related hyperphosphatemia that was resistant to standard treatments. Denosumab may represent a promising new therapy for treatment-resistant hyperphosphatemia in <i>FGF23</i> pathway disorders, though further studies are needed to confirm these findings and determine optimal management strategies.
Authors
- Vahid Ziaee (ORCID: https://orcid.org/0000-0003-4648-3573)
- Elham Zarei (ORCID: https://orcid.org/0000-0002-2130-405X)
- Sonya Dadakhani (ORCID: https://orcid.org/0000-0002-1996-0517)
- Mehdi Vafadar (ORCID: https://orcid.org/0000-0003-3809-6346)
Institutions
- Iran University of Medical Sciences (IR)
- University of Tabriz (IR)
- Children's Medical Center (IR)
Publication Details
- Journal
- Journal of Pediatric Endocrinology and Metabolism
- Published
- 2025-11-17
- DOI
- https://doi.org/10.1515/jpem-2025-0272
- Citations
- 1
- Primary Topic
- Parathyroid Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.43